Lexicon Pharma (LXRX) Tops Q4 EPS by 3c
Tweet
Share
E-mail
Get Alerts LXRX Hot Sheet
Price: $2.15 +6.97%
EPS Growth %: -600.0%
Financial Fact:
Total operating expenses: 62.65M
Today's EPS Names:
OCCI, MAYS, CRMT, More
EPS Growth %: -600.0%
Financial Fact:
Total operating expenses: 62.65M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
Lexicon Pharma (NASDAQ: LXRX) reported Q4 EPS of ($0.09), $0.03 better than the analyst estimate of ($0.12). Revenue for the quarter came in at $26.55 million versus the consensus estimate of $7.16 million.
For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla Crash Into Texas Home Now Under Federal Safety Probe - WSJ
- A.O. Smith executive chairman to retire, CEO to assume chairman role
- Rocket Lab launches U.S. Space Force mission in record 16 hours
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
